Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

425 ARTÍCULOS , VIENDO DEL 226 AL 240

Predictors of high hospital care and medication costs and cost trajectories in community-dwellers with Alzheimer's disease

Kalamägi J, Lavikainen P, Taipale H, Tanskanen A, Tiihonen J, Hartikainen S, Tolppanen AM.

Ann Med. 2019 Aug-Sep;51(5-6):294-305. doi: 10.1080/07853890.2019.1642507. Epub 2019 Aug 12.

Attention Measures of Accuracy, Variability, and Fatigue Detect Early Response to Donepezil in Alzheimer's Disease: A Randomized, Double-blind, Placebo-Controlled Pilot Trial

Vila-Castelar C, Ly JJ, Kaplan L, Van Dyk K, Berger JT, Macina LO, Stewart JL, Foldi NS.

Arch Clin Neuropsychol. 2019 May 1;34(3):277-289. doi: 10.1093/arclin/acy032.

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease

Farlow MR, Thompson RE, Wei LJ, Tuchman AJ, Grenier E, Crockford D, Wilke S, Benison J, Alkon DL.

J Alzheimers Dis. 2019;67(2):555-570. doi: 10.3233/JAD-180759.

Gabapentin and pregabalin to treat aggressivity in dementia: a systematic review and illustrative case report

Supasitthumrong T, Bolea-Alamanac BM, Asmer S, Woo VL, Abdool PS, Davies SJC.

Br J Clin Pharmacol. 2019 Apr;85(4):690-703. doi: 10.1111/bcp.13844. Epub 2019 Feb 8.

Quantifying placebo responses in clinical evaluation of neuropsychiatric symptoms in Alzheimer's disease

Zhang N, Lv Y, Li H, Chen J, Li Y, Yin F, Li L, Zheng Q.

Eur J Clin Pharmacol. 2019 Apr;75(4):497-509. doi: 10.1007/s00228-018-02620-x. Epub 2019 Jan 5.

Bad news and good news in AD, and how to reconcile them

Knopman DS.

Nat Rev Neurol. 2019 Feb;15(2):61-62. doi: 10.1038/s41582-018-0131-7.

Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Disease

Frölich L, Atri A, Ballard C, Tariot PN, Molinuevo JL, Boneva N, Geist MA, Raket LL, Cummings JL.

J Alzheimers Dis. 2019;67(1):303-313. doi: 10.3233/JAD-180595.

Contributions by the Brain Renin-Angiotensin System to Memory, Cognition, and Alzheimer's Disease

Wright JW, Harding JW.

J Alzheimers Dis. 2019;67(2):469-480. doi: 10.3233/JAD-181035.

The Potential Role of Dysregulated miRNAs in Alzheimer's Disease Pathogenesis and Progression

Patel AA, Ganepola GAP, Rutledge JR, Chang DH.

J Alzheimers Dis. 2019;67(4):1123-1145. doi: 10.3233/JAD-181078.

Present Algorithms and Future Treatments for Alzheimer's Disease

Grossberg GT, Tong G, Burke AD, Tariot PN.

J Alzheimers Dis. 2019;67(4):1157-1171. doi: 10.3233/JAD-180903.

Efficacy of Cilostazol Administration in Alzheimer's Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study

Lee JY, Lee H, Yoo HB, Choi JS, Jung HY, Yoon EJ, Kim H, Jung YH, Lee HY, Kim YK.

Neurotherapeutics. 2019 Apr;16(2):394-403. doi: 10.1007/s13311-018-00708-x.

Therapeutic Potential of AMP-Activated Protein Kinase in Alzheimer's Disease

Wang X, Zimmermann HR, Ma T.

J Alzheimers Dis. 2019;68(1):33-38. doi: 10.3233/JAD-181043.

The de-Alzheimerization of age-related dementias: implications for drug targets and approaches to effective therapeutics

Mullane K, Williams M.

Curr Opin Pharmacol. 2019 Feb;44:62-75. doi: 10.1016/j.coph.2019.01.004. Epub 2019 Feb 19.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias